compounded glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our Compounded GLP-1

Overall, six in ten adults (61%), including similar shares across age groups, say they think Medicare should cover the cost of these drugs when prescribed for weight loss for people who are overweight, a share that rises to about seven in ten (71%) among those who have ever taken these drugs

These medications, originally approved by the FDA for the treatment of Type 2 diabetes, have since been authorized for weight loss therapy and are now recommended by the American Diabetes Association as potential first-line options for both indications

But these days, the language of insanity is exactly how many people describe our society-level problems with chatbots

In a randomised, placebo-controlled double blinded phase 1 study of ascending single doses in healthy overweight humans, cotadutide was shown to be safe and, in common with the GLP-1 analogues, to be associated with dose-dependent gastrointestinal adverse events especially nausea and vomiting

* After subcutaneous administration

Its important to get these individual side effects reported to us, especially for new drugs, so that we can trend it, Ruck said